excel: 25397
excel with dem: 20383
remove no baseline cre: 18319
remove missing esrd_kt!=0, eGFR_CRE_baseline <10 : 18157
remove missing last_cre_date< ICI_date:17937 (17752 with labs
after ici date)
remove 216 placebo :17721
remove 3 death_date < ici_date(RPDR error): 17718
all
| Characteristic |
N = 15,065 |
| age_ici |
65 (56, 73) |
| male |
|
| 0 |
7,304 (48%) |
| 1 |
7,761 (52%) |
| Race |
|
| Asian |
509 (3.4%) |
| Black |
380 (2.5%) |
| Other/Unknown |
665 (4.4%) |
| White |
13,511 (90%) |
| Ethnic_Group |
|
| Hispanic |
262 (1.7%) |
| Non_hispanic |
13,898 (92%) |
| Other |
905 (6.0%) |
| ckd_progression |
|
| 0 |
14,675 (99%) |
| 1 |
104 (0.7%) |
| Missing |
286 |
| ckd_incidence |
|
| 0 |
14,051 (95%) |
| 1 |
728 (4.9%) |
| Missing |
286 |
| eskd_composite |
|
| 0 |
14,999 (100%) |
| 1 |
66 (0.4%) |
| ckd_composite |
|
| 0 |
14,188 (94%) |
| 1 |
877 (5.8%) |
| ckd_stage_baseline |
|
| 1 |
7,527 (50%) |
| 2 |
5,620 (37%) |
| 3 |
1,794 (12%) |
| 4 |
118 (0.8%) |
| 5 |
6 (<0.1%) |
| aki |
|
| 0 |
10,967 (73%) |
| 1 |
4,098 (27%) |
| dm |
|
| 0 |
15,065 (100%) |
| htn |
|
| 0 |
6,732 (45%) |
| 1 |
8,333 (55%) |
| cad |
|
| 0 |
12,098 (80%) |
| 1 |
2,967 (20%) |
| cirrhosis |
|
| 0 |
14,778 (98%) |
| 1 |
287 (1.9%) |
| cancer_type |
|
| breast |
1,087 (7.2%) |
| cutaneous / melanoma |
2,470 (16%) |
| endocrine |
4 (<0.1%) |
| gi |
2,119 (14%) |
| gu |
1,688 (11%) |
| gyn |
826 (5.5%) |
| head and neck |
1,115 (7.4%) |
| heme |
733 (4.9%) |
| neuro |
742 (4.9%) |
| sarcoma |
190 (1.3%) |
| thoracic |
4,091 (27%) |
| cancer_group |
|
| cutaneous / melanoma |
2,470 (16%) |
| gi |
2,119 (14%) |
| gu |
1,688 (11%) |
| gyn |
826 (5.5%) |
| other |
3,871 (26%) |
| thoracic |
4,091 (27%) |
| ace_arb |
|
| 0 |
9,539 (63%) |
| 1 |
5,526 (37%) |
| diu |
|
| 0 |
7,578 (50%) |
| 1 |
7,487 (50%) |
| ppi |
|
| 0 |
4,566 (30%) |
| 1 |
10,499 (70%) |
| steroids |
|
| 0 |
4,167 (28%) |
| 1 |
10,898 (72%) |
| smoking |
|
| 0 |
7,833 (52%) |
| 1 |
7,232 (48%) |
| Bevacizumab |
|
| 0 |
13,977 (93%) |
| 1 |
1,088 (7.2%) |
| Cisplatin |
|
| 0 |
13,125 (87%) |
| 1 |
1,940 (13%) |
| Carboplatin |
|
| 0 |
10,488 (70%) |
| 1 |
4,577 (30%) |
| Pemetrexed |
|
| 0 |
13,090 (87%) |
| 1 |
1,975 (13%) |
| Gemcitabine |
|
| 0 |
13,365 (89%) |
| 1 |
1,700 (11%) |
| Cetuximab |
|
| 0 |
14,718 (98%) |
| 1 |
347 (2.3%) |
| Trastuzumab |
|
| 0 |
14,668 (97%) |
| 1 |
397 (2.6%) |
| VEGF_TKI |
|
| 0 |
14,077 (93%) |
| 1 |
988 (6.6%) |
| statins |
|
| 0 |
8,934 (59%) |
| 1 |
6,131 (41%) |
| ICI_Class |
|
| PD1 |
10,528 (70%) |
| Combination |
1,765 (12%) |
| CTLA4 |
658 (4.4%) |
| PDL1 |
2,114 (14%) |
| nephrotoxic_chemo |
|
| 0 |
7,883 (52%) |
| 1 |
7,182 (48%) |
| pre_CRE_180days |
0.83 (0.69, 1.01) |
| pre_HGB_180days |
12.30 (10.90, 13.60) |
| Missing |
6 |
| pre_ALB_180days |
4.00 (3.70, 4.30) |
| Missing |
30 |
| eGFR_CRE_baseline |
90 (73, 101) |
1year
| Characteristic |
N = 7,927 |
| age_ici |
65 (55, 73) |
| male |
|
| 0 |
3,905 (49%) |
| 1 |
4,022 (51%) |
| Race |
|
| Asian |
232 (2.9%) |
| Black |
184 (2.3%) |
| Other/Unknown |
320 (4.0%) |
| White |
7,191 (91%) |
| Ethnic_Group |
|
| Hispanic |
130 (1.6%) |
| Non_hispanic |
7,315 (92%) |
| Other |
482 (6.1%) |
| ckd_incidence_1year |
|
| 0 |
7,658 (97%) |
| 1 |
269 (3.4%) |
| ckd_progression_1year |
|
| 0 |
7,900 (100%) |
| 1 |
27 (0.3%) |
| eskd_composite_1year |
|
| 0 |
7,908 (100%) |
| 1 |
19 (0.2%) |
| ckd_composite_1year |
|
| 0 |
7,615 (96%) |
| 1 |
312 (3.9%) |
| ckd_stage_1year |
|
| 1 |
3,346 (42%) |
| 2 |
3,329 (42%) |
| 3 |
1,185 (15%) |
| 4 |
61 (0.8%) |
| 5 |
6 (<0.1%) |
| ckd_stage_baseline |
|
| 1 |
3,797 (48%) |
| 2 |
3,202 (40%) |
| 3 |
882 (11%) |
| 4 |
45 (0.6%) |
| 5 |
1 (<0.1%) |
| aki |
|
| 0 |
5,504 (69%) |
| 1 |
2,423 (31%) |
| dm |
|
| 0 |
7,927 (100%) |
| htn |
|
| 0 |
3,640 (46%) |
| 1 |
4,287 (54%) |
| cad |
|
| 0 |
6,539 (82%) |
| 1 |
1,388 (18%) |
| cirrhosis |
|
| 0 |
7,819 (99%) |
| 1 |
108 (1.4%) |
| cancer_type |
|
| breast |
680 (8.6%) |
| cutaneous / melanoma |
1,709 (22%) |
| endocrine |
1 (<0.1%) |
| gi |
840 (11%) |
| gu |
1,000 (13%) |
| gyn |
437 (5.5%) |
| head and neck |
520 (6.6%) |
| heme |
435 (5.5%) |
| neuro |
266 (3.4%) |
| sarcoma |
95 (1.2%) |
| thoracic |
1,944 (25%) |
| cancer_group |
|
| cutaneous / melanoma |
1,709 (22%) |
| gi |
840 (11%) |
| gu |
1,000 (13%) |
| gyn |
437 (5.5%) |
| other |
1,997 (25%) |
| thoracic |
1,944 (25%) |
| ace_arb |
|
| 0 |
4,767 (60%) |
| 1 |
3,160 (40%) |
| diu |
|
| 0 |
3,987 (50%) |
| 1 |
3,940 (50%) |
| ppi |
|
| 0 |
2,306 (29%) |
| 1 |
5,621 (71%) |
| steroids |
|
| 0 |
2,260 (29%) |
| 1 |
5,667 (71%) |
| smoking |
|
| 0 |
4,005 (51%) |
| 1 |
3,922 (49%) |
| statins |
|
| 0 |
4,383 (55%) |
| 1 |
3,544 (45%) |
| ICI_Class |
|
| PD1 |
5,410 (68%) |
| Combination |
1,012 (13%) |
| CTLA4 |
377 (4.8%) |
| PDL1 |
1,128 (14%) |
| nephrotoxic_chemo |
|
| 0 |
4,180 (53%) |
| 1 |
3,747 (47%) |
| pre_CRE_180days |
0.85 (0.71, 1.02) |
| pre_HGB_180days |
12.80 (11.50, 13.90) |
| Missing |
3 |
| pre_ALB_180days |
4.20 (3.90, 4.40) |
| Missing |
18 |
| eGFR_CRE_baseline |
89 (73, 100) |
2year
| Characteristic |
N = 5,093 |
| age_ici |
65 (55, 72) |
| male |
|
| 0 |
2,452 (48%) |
| 1 |
2,641 (52%) |
| Race |
|
| Asian |
134 (2.6%) |
| Black |
101 (2.0%) |
| Other/Unknown |
195 (3.8%) |
| White |
4,663 (92%) |
| Ethnic_Group |
|
| Hispanic |
69 (1.4%) |
| Non_hispanic |
4,698 (92%) |
| Other |
326 (6.4%) |
| ckd_incidence_2year |
|
| 0 |
4,743 (93%) |
| 1 |
350 (6.9%) |
| ckd_progression_2year |
|
| 0 |
5,058 (99%) |
| 1 |
35 (0.7%) |
| eskd_composite_2year |
|
| 0 |
5,079 (100%) |
| 1 |
14 (0.3%) |
| ckd_composite_2year |
|
| 0 |
4,699 (92%) |
| 1 |
394 (7.7%) |
| ckd_stage_1year |
|
| 1 |
2,033 (40%) |
| 2 |
2,264 (44%) |
| 3 |
763 (15%) |
| 4 |
32 (0.6%) |
| 5 |
1 (<0.1%) |
| ckd_stage_2year |
|
| 1 |
1,948 (38%) |
| 2 |
2,297 (45%) |
| 3 |
810 (16%) |
| 4 |
36 (0.7%) |
| 5 |
2 (<0.1%) |
| ckd_stage_baseline |
|
| 1 |
2,400 (47%) |
| 2 |
2,124 (42%) |
| 3 |
544 (11%) |
| 4 |
24 (0.5%) |
| 5 |
1 (<0.1%) |
| aki |
|
| 0 |
3,571 (70%) |
| 1 |
1,522 (30%) |
| dm |
|
| 0 |
5,093 (100%) |
| htn |
|
| 0 |
2,362 (46%) |
| 1 |
2,731 (54%) |
| cad |
|
| 0 |
4,214 (83%) |
| 1 |
879 (17%) |
| cirrhosis |
|
| 0 |
5,040 (99%) |
| 1 |
53 (1.0%) |
| cancer_type |
|
| breast |
372 (7.3%) |
| cutaneous / melanoma |
1,302 (26%) |
| endocrine |
1 (<0.1%) |
| gi |
431 (8.5%) |
| gu |
682 (13%) |
| gyn |
269 (5.3%) |
| head and neck |
324 (6.4%) |
| heme |
319 (6.3%) |
| neuro |
137 (2.7%) |
| sarcoma |
58 (1.1%) |
| thoracic |
1,198 (24%) |
| cancer_group |
|
| cutaneous / melanoma |
1,302 (26%) |
| gi |
431 (8.5%) |
| gu |
682 (13%) |
| gyn |
269 (5.3%) |
| other |
1,211 (24%) |
| thoracic |
1,198 (24%) |
| ace_arb |
|
| 0 |
3,001 (59%) |
| 1 |
2,092 (41%) |
| diu |
|
| 0 |
2,611 (51%) |
| 1 |
2,482 (49%) |
| ppi |
|
| 0 |
1,473 (29%) |
| 1 |
3,620 (71%) |
| steroids |
|
| 0 |
1,480 (29%) |
| 1 |
3,613 (71%) |
| smoking |
|
| 0 |
2,576 (51%) |
| 1 |
2,517 (49%) |
| statins |
|
| 0 |
2,721 (53%) |
| 1 |
2,372 (47%) |
| ICI_Class |
|
| PD1 |
3,415 (67%) |
| Combination |
707 (14%) |
| CTLA4 |
287 (5.6%) |
| PDL1 |
684 (13%) |
| nephrotoxic_chemo |
|
| 0 |
2,941 (58%) |
| 1 |
2,152 (42%) |
| pre_CRE_180days |
0.86 (0.72, 1.02) |
| pre_HGB_180days |
12.90 (11.70, 14.10) |
| Missing |
2 |
| pre_ALB_180days |
4.20 (3.90, 4.40) |
| Missing |
13 |
| eGFR_CRE_baseline |
89 (73, 100) |
3year
| Characteristic |
N = 3,209 |
| age_ici |
64 (55, 71) |
| male |
|
| 0 |
1,499 (47%) |
| 1 |
1,710 (53%) |
| Race |
|
| Asian |
67 (2.1%) |
| Black |
54 (1.7%) |
| Other/Unknown |
118 (3.7%) |
| White |
2,970 (93%) |
| Ethnic_Group |
|
| Hispanic |
40 (1.2%) |
| Non_hispanic |
2,968 (92%) |
| Other |
201 (6.3%) |
| ckd_incidence_3year |
|
| 0 |
2,918 (91%) |
| 1 |
291 (9.1%) |
| ckd_progression_3year |
|
| 0 |
3,172 (99%) |
| 1 |
37 (1.2%) |
| eskd_composite_3year |
|
| 0 |
3,198 (100%) |
| 1 |
11 (0.3%) |
| ckd_composite_3year |
|
| 0 |
2,875 (90%) |
| 1 |
334 (10%) |
| ckd_stage_1year |
|
| 1 |
1,281 (40%) |
| 2 |
1,450 (45%) |
| 3 |
459 (14%) |
| 4 |
18 (0.6%) |
| 5 |
1 (<0.1%) |
| ckd_stage_2year |
|
| 1 |
1,207 (38%) |
| 2 |
1,499 (47%) |
| 3 |
486 (15%) |
| 4 |
16 (0.5%) |
| 5 |
1 (<0.1%) |
| ckd_stage_3year |
|
| 1 |
1,163 (36%) |
| 2 |
1,529 (48%) |
| 3 |
482 (15%) |
| 4 |
30 (0.9%) |
| 5 |
5 (0.2%) |
| ckd_stage_baseline |
|
| 1 |
1,513 (47%) |
| 2 |
1,349 (42%) |
| 3 |
336 (10%) |
| 4 |
10 (0.3%) |
| 5 |
1 (<0.1%) |
| aki |
|
| 0 |
2,261 (70%) |
| 1 |
948 (30%) |
| dm |
|
| 0 |
3,209 (100%) |
| htn |
|
| 0 |
1,458 (45%) |
| 1 |
1,751 (55%) |
| cad |
|
| 0 |
2,675 (83%) |
| 1 |
534 (17%) |
| cirrhosis |
|
| 0 |
3,181 (99%) |
| 1 |
28 (0.9%) |
| cancer_type |
|
| breast |
173 (5.4%) |
| cutaneous / melanoma |
947 (30%) |
| endocrine |
0 (0%) |
| gi |
223 (6.9%) |
| gu |
448 (14%) |
| gyn |
140 (4.4%) |
| head and neck |
213 (6.6%) |
| heme |
220 (6.9%) |
| neuro |
84 (2.6%) |
| sarcoma |
32 (1.0%) |
| thoracic |
729 (23%) |
| cancer_group |
|
| cutaneous / melanoma |
947 (30%) |
| gi |
223 (6.9%) |
| gu |
448 (14%) |
| gyn |
140 (4.4%) |
| other |
722 (22%) |
| thoracic |
729 (23%) |
| ace_arb |
|
| 0 |
1,841 (57%) |
| 1 |
1,368 (43%) |
| diu |
|
| 0 |
1,606 (50%) |
| 1 |
1,603 (50%) |
| ppi |
|
| 0 |
899 (28%) |
| 1 |
2,310 (72%) |
| steroids |
|
| 0 |
929 (29%) |
| 1 |
2,280 (71%) |
| smoking |
|
| 0 |
1,589 (50%) |
| 1 |
1,620 (50%) |
| statins |
|
| 0 |
1,649 (51%) |
| 1 |
1,560 (49%) |
| ICI_Class |
|
| PD1 |
2,139 (67%) |
| Combination |
453 (14%) |
| CTLA4 |
198 (6.2%) |
| PDL1 |
419 (13%) |
| nephrotoxic_chemo |
|
| 0 |
1,986 (62%) |
| 1 |
1,223 (38%) |
| pre_CRE_180days |
0.87 (0.73, 1.03) |
| pre_HGB_180days |
13.00 (11.80, 14.20) |
| Missing |
2 |
| pre_ALB_180days |
4.20 (3.90, 4.40) |
| Missing |
10 |
| eGFR_CRE_baseline |
89 (73, 100) |
4year
| Characteristic |
N = 2,155 |
| age_ici |
63 (54, 71) |
| male |
|
| 0 |
1,002 (46%) |
| 1 |
1,153 (54%) |
| Race |
|
| Asian |
44 (2.0%) |
| Black |
32 (1.5%) |
| Other/Unknown |
73 (3.4%) |
| White |
2,006 (93%) |
| Ethnic_Group |
|
| Hispanic |
24 (1.1%) |
| Non_hispanic |
1,988 (92%) |
| Other |
143 (6.6%) |
| ckd_incidence_4year |
|
| 0 |
1,925 (89%) |
| 1 |
230 (11%) |
| ckd_progression_4year |
|
| 0 |
2,130 (99%) |
| 1 |
25 (1.2%) |
| eskd_composite_4year |
|
| 0 |
2,147 (100%) |
| 1 |
8 (0.4%) |
| ckd_composite_4year |
|
| 0 |
1,894 (88%) |
| 1 |
261 (12%) |
| ckd_stage_1year |
|
| 1 |
860 (40%) |
| 2 |
997 (46%) |
| 3 |
286 (13%) |
| 4 |
11 (0.5%) |
| 5 |
1 (<0.1%) |
| ckd_stage_2year |
|
| 1 |
825 (38%) |
| 2 |
1,018 (47%) |
| 3 |
302 (14%) |
| 4 |
9 (0.4%) |
| 5 |
1 (<0.1%) |
| ckd_stage_3year |
|
| 1 |
773 (36%) |
| 2 |
1,062 (49%) |
| 3 |
305 (14%) |
| 4 |
13 (0.6%) |
| 5 |
2 (<0.1%) |
| ckd_stage_4year |
|
| 1 |
800 (37%) |
| 2 |
997 (46%) |
| 3 |
338 (16%) |
| 4 |
19 (0.9%) |
| 5 |
1 (<0.1%) |
| ckd_stage_baseline |
|
| 1 |
1,048 (49%) |
| 2 |
889 (41%) |
| 3 |
213 (9.9%) |
| 4 |
4 (0.2%) |
| 5 |
1 (<0.1%) |
| aki |
|
| 0 |
1,521 (71%) |
| 1 |
634 (29%) |
| dm |
|
| 0 |
2,155 (100%) |
| htn |
|
| 0 |
959 (45%) |
| 1 |
1,196 (55%) |
| cad |
|
| 0 |
1,795 (83%) |
| 1 |
360 (17%) |
| cirrhosis |
|
| 0 |
2,139 (99%) |
| 1 |
16 (0.7%) |
| cancer_type |
|
| breast |
97 (4.5%) |
| cutaneous / melanoma |
729 (34%) |
| endocrine |
0 (0%) |
| gi |
126 (5.8%) |
| gu |
282 (13%) |
| gyn |
83 (3.9%) |
| head and neck |
147 (6.8%) |
| heme |
156 (7.2%) |
| neuro |
47 (2.2%) |
| sarcoma |
19 (0.9%) |
| thoracic |
469 (22%) |
| cancer_group |
|
| cutaneous / melanoma |
729 (34%) |
| gi |
126 (5.8%) |
| gu |
282 (13%) |
| gyn |
83 (3.9%) |
| other |
466 (22%) |
| thoracic |
469 (22%) |
| ace_arb |
|
| 0 |
1,229 (57%) |
| 1 |
926 (43%) |
| diu |
|
| 0 |
1,091 (51%) |
| 1 |
1,064 (49%) |
| ppi |
|
| 0 |
552 (26%) |
| 1 |
1,603 (74%) |
| steroids |
|
| 0 |
638 (30%) |
| 1 |
1,517 (70%) |
| smoking |
|
| 0 |
1,067 (50%) |
| 1 |
1,088 (50%) |
| statins |
|
| 0 |
1,086 (50%) |
| 1 |
1,069 (50%) |
| ICI_Class |
|
| PD1 |
1,432 (66%) |
| Combination |
297 (14%) |
| CTLA4 |
146 (6.8%) |
| PDL1 |
280 (13%) |
| nephrotoxic_chemo |
|
| 0 |
1,406 (65%) |
| 1 |
749 (35%) |
| pre_CRE_180days |
0.86 (0.72, 1.02) |
| pre_HGB_180days |
13.10 (11.90, 14.20) |
| pre_ALB_180days |
4.20 (3.90, 4.40) |
| Missing |
6 |
| eGFR_CRE_baseline |
89 (75, 100) |
5year
| Characteristic |
N = 1,484 |
| age_ici |
62 (53, 70) |
| male |
|
| 0 |
687 (46%) |
| 1 |
797 (54%) |
| Race |
|
| Asian |
34 (2.3%) |
| Black |
15 (1.0%) |
| Other/Unknown |
45 (3.0%) |
| White |
1,390 (94%) |
| Ethnic_Group |
|
| Hispanic |
17 (1.1%) |
| Non_hispanic |
1,365 (92%) |
| Other |
102 (6.9%) |
| ckd_incidence_5year |
|
| 0 |
1,304 (88%) |
| 1 |
180 (12%) |
| ckd_progression_5year |
|
| 0 |
1,462 (99%) |
| 1 |
22 (1.5%) |
| eskd_composite_5year |
|
| 0 |
1,475 (99%) |
| 1 |
9 (0.6%) |
| ckd_composite_5year |
|
| 0 |
1,276 (86%) |
| 1 |
208 (14%) |
| ckd_stage_1year |
|
| 1 |
609 (41%) |
| 2 |
678 (46%) |
| 3 |
190 (13%) |
| 4 |
6 (0.4%) |
| 5 |
1 (<0.1%) |
| ckd_stage_2year |
|
| 1 |
570 (38%) |
| 2 |
712 (48%) |
| 3 |
196 (13%) |
| 4 |
5 (0.3%) |
| 5 |
1 (<0.1%) |
| ckd_stage_3year |
|
| 1 |
528 (36%) |
| 2 |
740 (50%) |
| 3 |
210 (14%) |
| 4 |
4 (0.3%) |
| 5 |
2 (0.1%) |
| ckd_stage_4year |
|
| 1 |
550 (37%) |
| 2 |
700 (47%) |
| 3 |
223 (15%) |
| 4 |
10 (0.7%) |
| 5 |
1 (<0.1%) |
| ckd_stage_5year |
|
| 1 |
567 (38%) |
| 2 |
680 (46%) |
| 3 |
223 (15%) |
| 4 |
12 (0.8%) |
| 5 |
2 (0.1%) |
| ckd_stage_baseline |
|
| 1 |
741 (50%) |
| 2 |
604 (41%) |
| 3 |
136 (9.2%) |
| 4 |
3 (0.2%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
1,053 (71%) |
| 1 |
431 (29%) |
| dm |
|
| 0 |
1,484 (100%) |
| htn |
|
| 0 |
661 (45%) |
| 1 |
823 (55%) |
| cad |
|
| 0 |
1,247 (84%) |
| 1 |
237 (16%) |
| cirrhosis |
|
| 0 |
1,473 (99%) |
| 1 |
11 (0.7%) |
| cancer_type |
|
| breast |
59 (4.0%) |
| cutaneous / melanoma |
577 (39%) |
| endocrine |
0 (0%) |
| gi |
67 (4.5%) |
| gu |
180 (12%) |
| gyn |
54 (3.6%) |
| head and neck |
101 (6.8%) |
| heme |
101 (6.8%) |
| neuro |
27 (1.8%) |
| sarcoma |
8 (0.5%) |
| thoracic |
310 (21%) |
| cancer_group |
|
| cutaneous / melanoma |
577 (39%) |
| gi |
67 (4.5%) |
| gu |
180 (12%) |
| gyn |
54 (3.6%) |
| other |
296 (20%) |
| thoracic |
310 (21%) |
| ace_arb |
|
| 0 |
848 (57%) |
| 1 |
636 (43%) |
| diu |
|
| 0 |
744 (50%) |
| 1 |
740 (50%) |
| ppi |
|
| 0 |
367 (25%) |
| 1 |
1,117 (75%) |
| steroids |
|
| 0 |
443 (30%) |
| 1 |
1,041 (70%) |
| smoking |
|
| 0 |
741 (50%) |
| 1 |
743 (50%) |
| statins |
|
| 0 |
733 (49%) |
| 1 |
751 (51%) |
| ICI_Class |
|
| PD1 |
1,007 (68%) |
| Combination |
191 (13%) |
| CTLA4 |
110 (7.4%) |
| PDL1 |
176 (12%) |
| nephrotoxic_chemo |
|
| 0 |
997 (67%) |
| 1 |
487 (33%) |
| pre_CRE_180days |
0.86 (0.72, 1.02) |
| pre_HGB_180days |
13.20 (12.00, 14.20) |
| pre_ALB_180days |
4.20 (3.90, 4.40) |
| Missing |
5 |
| eGFR_CRE_baseline |
90 (75, 101) |
6year
| Characteristic |
N = 965 |
| age_ici |
61 (52, 69) |
| male |
|
| 0 |
457 (47%) |
| 1 |
508 (53%) |
| Race |
|
| Asian |
16 (1.7%) |
| Black |
14 (1.5%) |
| Other/Unknown |
28 (2.9%) |
| White |
907 (94%) |
| Ethnic_Group |
|
| Hispanic |
9 (0.9%) |
| Non_hispanic |
884 (92%) |
| Other |
72 (7.5%) |
| ckd_incidence_6year |
|
| 0 |
839 (87%) |
| 1 |
126 (13%) |
| ckd_progression_6year |
|
| 0 |
947 (98%) |
| 1 |
18 (1.9%) |
| eskd_composite_6year |
|
| 0 |
958 (99%) |
| 1 |
7 (0.7%) |
| ckd_composite_6year |
147 (15%) |
| ckd_stage_1year |
|
| 1 |
421 (44%) |
| 2 |
432 (45%) |
| 3 |
108 (11%) |
| 4 |
3 (0.3%) |
| 5 |
1 (0.1%) |
| ckd_stage_2year |
|
| 1 |
378 (39%) |
| 2 |
471 (49%) |
| 3 |
113 (12%) |
| 4 |
2 (0.2%) |
| 5 |
1 (0.1%) |
| ckd_stage_3year |
|
| 1 |
343 (36%) |
| 2 |
493 (51%) |
| 3 |
126 (13%) |
| 4 |
2 (0.2%) |
| 5 |
1 (0.1%) |
| ckd_stage_4year |
|
| 1 |
367 (38%) |
| 2 |
462 (48%) |
| 3 |
131 (14%) |
| 4 |
4 (0.4%) |
| 5 |
1 (0.1%) |
| ckd_stage_5year |
|
| 1 |
385 (40%) |
| 2 |
444 (46%) |
| 3 |
127 (13%) |
| 4 |
7 (0.7%) |
| 5 |
2 (0.2%) |
| ckd_stage_6year |
|
| 1 |
372 (39%) |
| 2 |
447 (46%) |
| 3 |
137 (14%) |
| 4 |
6 (0.6%) |
| 5 |
3 (0.3%) |
| ckd_stage_baseline |
|
| 1 |
496 (51%) |
| 2 |
383 (40%) |
| 3 |
85 (8.8%) |
| 4 |
1 (0.1%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
701 (73%) |
| 1 |
264 (27%) |
| dm |
|
| 0 |
965 (100%) |
| htn |
|
| 0 |
422 (44%) |
| 1 |
543 (56%) |
| cad |
|
| 0 |
817 (85%) |
| 1 |
148 (15%) |
| cirrhosis |
|
| 0 |
957 (99%) |
| 1 |
8 (0.8%) |
| cancer_type |
|
| breast |
38 (3.9%) |
| cutaneous / melanoma |
417 (43%) |
| endocrine |
0 (0%) |
| gi |
28 (2.9%) |
| gu |
106 (11%) |
| gyn |
35 (3.6%) |
| head and neck |
62 (6.4%) |
| heme |
73 (7.6%) |
| neuro |
12 (1.2%) |
| sarcoma |
2 (0.2%) |
| thoracic |
192 (20%) |
| cancer_group |
|
| cutaneous / melanoma |
417 (43%) |
| gi |
28 (2.9%) |
| gu |
106 (11%) |
| gyn |
35 (3.6%) |
| other |
187 (19%) |
| thoracic |
192 (20%) |
| ace_arb |
|
| 0 |
557 (58%) |
| 1 |
408 (42%) |
| diu |
|
| 0 |
497 (52%) |
| 1 |
468 (48%) |
| ppi |
|
| 0 |
215 (22%) |
| 1 |
750 (78%) |
| steroids |
|
| 0 |
283 (29%) |
| 1 |
682 (71%) |
| smoking |
|
| 0 |
479 (50%) |
| 1 |
486 (50%) |
| statins |
|
| 0 |
475 (49%) |
| 1 |
490 (51%) |
| ICI_Class |
|
| PD1 |
646 (67%) |
| Combination |
112 (12%) |
| CTLA4 |
96 (9.9%) |
| PDL1 |
111 (12%) |
| nephrotoxic_chemo |
|
| 0 |
669 (69%) |
| 1 |
296 (31%) |
| pre_CRE_180days |
0.86 (0.72, 1.02) |
| pre_HGB_180days |
13.30 (12.20, 14.20) |
| pre_ALB_180days |
4.20 (4.00, 4.40) |
| Missing |
3 |
| eGFR_CRE_baseline |
91 (75, 101) |
7year
| Characteristic |
N = 584 |
| age_ici |
61 (52, 68) |
| male |
|
| 0 |
271 (46%) |
| 1 |
313 (54%) |
| Race |
|
| Asian |
8 (1.4%) |
| Black |
9 (1.5%) |
| Other/Unknown |
17 (2.9%) |
| White |
550 (94%) |
| Ethnic_Group |
|
| Hispanic |
6 (1.0%) |
| Non_hispanic |
534 (91%) |
| Other |
44 (7.5%) |
| ckd_incidence_7year |
|
| 0 |
500 (86%) |
| 1 |
84 (14%) |
| ckd_progression_7year |
|
| 0 |
573 (98%) |
| 1 |
11 (1.9%) |
| eskd_composite_7year |
|
| 0 |
576 (99%) |
| 1 |
8 (1.4%) |
| ckd_composite_7year |
97 (17%) |
| ckd_stage_1year |
|
| 1 |
261 (45%) |
| 2 |
260 (45%) |
| 3 |
60 (10%) |
| 4 |
2 (0.3%) |
| 5 |
1 (0.2%) |
| ckd_stage_2year |
|
| 1 |
242 (41%) |
| 2 |
275 (47%) |
| 3 |
65 (11%) |
| 4 |
1 (0.2%) |
| 5 |
1 (0.2%) |
| ckd_stage_3year |
|
| 1 |
220 (38%) |
| 2 |
287 (49%) |
| 3 |
75 (13%) |
| 4 |
1 (0.2%) |
| 5 |
1 (0.2%) |
| ckd_stage_4year |
|
| 1 |
227 (39%) |
| 2 |
276 (47%) |
| 3 |
76 (13%) |
| 4 |
4 (0.7%) |
| 5 |
1 (0.2%) |
| ckd_stage_5year |
|
| 1 |
242 (41%) |
| 2 |
261 (45%) |
| 3 |
75 (13%) |
| 4 |
4 (0.7%) |
| 5 |
2 (0.3%) |
| ckd_stage_6year |
|
| 1 |
235 (40%) |
| 2 |
268 (46%) |
| 3 |
75 (13%) |
| 4 |
4 (0.7%) |
| 5 |
2 (0.3%) |
| ckd_stage_7year |
|
| 1 |
222 (38%) |
| 2 |
280 (48%) |
| 3 |
72 (12%) |
| 4 |
7 (1.2%) |
| 5 |
3 (0.5%) |
| ckd_stage_baseline |
|
| 1 |
310 (53%) |
| 2 |
225 (39%) |
| 3 |
48 (8.2%) |
| 4 |
1 (0.2%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
433 (74%) |
| 1 |
151 (26%) |
| dm |
|
| 0 |
584 (100%) |
| htn |
|
| 0 |
245 (42%) |
| 1 |
339 (58%) |
| cad |
|
| 0 |
504 (86%) |
| 1 |
80 (14%) |
| cirrhosis |
|
| 0 |
580 (99%) |
| 1 |
4 (0.7%) |
| cancer_type |
|
| breast |
23 (3.9%) |
| cutaneous / melanoma |
296 (51%) |
| endocrine |
0 (0%) |
| gi |
13 (2.2%) |
| gu |
56 (9.6%) |
| gyn |
14 (2.4%) |
| head and neck |
25 (4.3%) |
| heme |
56 (9.6%) |
| neuro |
7 (1.2%) |
| sarcoma |
0 (0%) |
| thoracic |
94 (16%) |
| cancer_group |
|
| cutaneous / melanoma |
296 (51%) |
| gi |
13 (2.2%) |
| gu |
56 (9.6%) |
| gyn |
14 (2.4%) |
| other |
111 (19%) |
| thoracic |
94 (16%) |
| ace_arb |
|
| 0 |
340 (58%) |
| 1 |
244 (42%) |
| diu |
|
| 0 |
293 (50%) |
| 1 |
291 (50%) |
| ppi |
|
| 0 |
118 (20%) |
| 1 |
466 (80%) |
| steroids |
|
| 0 |
180 (31%) |
| 1 |
404 (69%) |
| smoking |
|
| 0 |
295 (51%) |
| 1 |
289 (49%) |
| statins |
|
| 0 |
284 (49%) |
| 1 |
300 (51%) |
| ICI_Class |
|
| PD1 |
372 (64%) |
| Combination |
77 (13%) |
| CTLA4 |
78 (13%) |
| PDL1 |
57 (9.8%) |
| nephrotoxic_chemo |
|
| 0 |
440 (75%) |
| 1 |
144 (25%) |
| pre_CRE_180days |
0.86 (0.73, 1.02) |
| pre_HGB_180days |
13.30 (12.10, 14.20) |
| pre_ALB_180days |
4.20 (4.00, 4.40) |
| Missing |
3 |
| eGFR_CRE_baseline |
91 (75, 102) |
8year
| Characteristic |
N = 347 |
| age_ici |
61 (52, 68) |
| male |
|
| 0 |
148 (43%) |
| 1 |
199 (57%) |
| Race |
|
| Asian |
5 (1.4%) |
| Black |
4 (1.2%) |
| Other/Unknown |
6 (1.7%) |
| White |
332 (96%) |
| Ethnic_Group |
|
| Hispanic |
5 (1.4%) |
| Non_hispanic |
311 (90%) |
| Other |
31 (8.9%) |
| ckd_incidence_8year |
|
| 0 |
296 (85%) |
| 1 |
51 (15%) |
| ckd_progression_8year |
|
| 0 |
344 (99%) |
| 1 |
3 (0.9%) |
| eskd_composite_8year |
|
| 0 |
343 (99%) |
| 1 |
4 (1.2%) |
| ckd_composite_8year |
56 (16%) |
| ckd_stage_1year |
|
| 1 |
156 (45%) |
| 2 |
158 (46%) |
| 3 |
33 (9.5%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_2year |
|
| 1 |
147 (42%) |
| 2 |
163 (47%) |
| 3 |
37 (11%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_3year |
|
| 1 |
134 (39%) |
| 2 |
173 (50%) |
| 3 |
40 (12%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_4year |
|
| 1 |
138 (40%) |
| 2 |
167 (48%) |
| 3 |
41 (12%) |
| 4 |
1 (0.3%) |
| 5 |
0 (0%) |
| ckd_stage_5year |
|
| 1 |
144 (41%) |
| 2 |
157 (45%) |
| 3 |
44 (13%) |
| 4 |
2 (0.6%) |
| 5 |
0 (0%) |
| ckd_stage_6year |
|
| 1 |
142 (41%) |
| 2 |
158 (46%) |
| 3 |
45 (13%) |
| 4 |
2 (0.6%) |
| 5 |
0 (0%) |
| ckd_stage_7year |
|
| 1 |
140 (40%) |
| 2 |
166 (48%) |
| 3 |
38 (11%) |
| 4 |
3 (0.9%) |
| 5 |
0 (0%) |
| ckd_stage_8year |
|
| 1 |
137 (39%) |
| 2 |
166 (48%) |
| 3 |
40 (12%) |
| 4 |
4 (1.2%) |
| 5 |
0 (0%) |
| ckd_stage_baseline |
|
| 1 |
189 (54%) |
| 2 |
132 (38%) |
| 3 |
26 (7.5%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
257 (74%) |
| 1 |
90 (26%) |
| dm |
|
| 0 |
347 (100%) |
| htn |
|
| 0 |
148 (43%) |
| 1 |
199 (57%) |
| cad |
|
| 0 |
303 (87%) |
| 1 |
44 (13%) |
| cirrhosis |
|
| 0 |
346 (100%) |
| 1 |
1 (0.3%) |
| cancer_type |
|
| breast |
10 (2.9%) |
| cutaneous / melanoma |
206 (59%) |
| endocrine |
0 (0%) |
| gi |
5 (1.4%) |
| gu |
32 (9.2%) |
| gyn |
6 (1.7%) |
| head and neck |
8 (2.3%) |
| heme |
36 (10%) |
| neuro |
2 (0.6%) |
| sarcoma |
0 (0%) |
| thoracic |
42 (12%) |
| cancer_group |
|
| cutaneous / melanoma |
206 (59%) |
| gi |
5 (1.4%) |
| gu |
32 (9.2%) |
| gyn |
6 (1.7%) |
| other |
56 (16%) |
| thoracic |
42 (12%) |
| ace_arb |
|
| 0 |
199 (57%) |
| 1 |
148 (43%) |
| diu |
|
| 0 |
178 (51%) |
| 1 |
169 (49%) |
| ppi |
|
| 0 |
72 (21%) |
| 1 |
275 (79%) |
| steroids |
|
| 0 |
126 (36%) |
| 1 |
221 (64%) |
| smoking |
|
| 0 |
188 (54%) |
| 1 |
159 (46%) |
| statins |
|
| 0 |
169 (49%) |
| 1 |
178 (51%) |
| ICI_Class |
|
| PD1 |
190 (55%) |
| Combination |
58 (17%) |
| CTLA4 |
65 (19%) |
| PDL1 |
34 (9.8%) |
| nephrotoxic_chemo |
|
| 0 |
277 (80%) |
| 1 |
70 (20%) |
| pre_CRE_180days |
0.86 (0.74, 1.02) |
| pre_HGB_180days |
13.30 (12.00, 14.20) |
| pre_ALB_180days |
4.20 (4.00, 4.50) |
| Missing |
2 |
| eGFR_CRE_baseline |
91 (76, 101) |
9year
| Characteristic |
N = 187 |
| age_ici |
60 (52, 68) |
| male |
|
| 0 |
84 (45%) |
| 1 |
103 (55%) |
| Race |
|
| Asian |
2 (1.1%) |
| Black |
2 (1.1%) |
| Other/Unknown |
3 (1.6%) |
| White |
180 (96%) |
| Ethnic_Group |
|
| Hispanic |
1 (0.5%) |
| Non_hispanic |
170 (91%) |
| Other |
16 (8.6%) |
| ckd_incidence_9year |
|
| 0 |
159 (85%) |
| 1 |
28 (15%) |
| ckd_progression_9year |
|
| 0 |
186 (99%) |
| 1 |
1 (0.5%) |
| eskd_composite_9year |
|
| 0 |
186 (99%) |
| 1 |
1 (0.5%) |
| ckd_composite_9year |
29 (16%) |
| ckd_stage_1year |
|
| 1 |
86 (46%) |
| 2 |
86 (46%) |
| 3 |
15 (8.0%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_2year |
|
| 1 |
82 (44%) |
| 2 |
90 (48%) |
| 3 |
15 (8.0%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_3year |
|
| 1 |
75 (40%) |
| 2 |
96 (51%) |
| 3 |
16 (8.6%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_4year |
|
| 1 |
81 (43%) |
| 2 |
87 (47%) |
| 3 |
19 (10%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_5year |
|
| 1 |
83 (44%) |
| 2 |
81 (43%) |
| 3 |
23 (12%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_6year |
|
| 1 |
77 (41%) |
| 2 |
86 (46%) |
| 3 |
24 (13%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_7year |
|
| 1 |
82 (44%) |
| 2 |
82 (44%) |
| 3 |
23 (12%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_8year |
|
| 1 |
82 (44%) |
| 2 |
81 (43%) |
| 3 |
24 (13%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_9year |
|
| 1 |
82 (44%) |
| 2 |
78 (42%) |
| 3 |
27 (14%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_baseline |
|
| 1 |
100 (53%) |
| 2 |
74 (40%) |
| 3 |
13 (7.0%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
142 (76%) |
| 1 |
45 (24%) |
| dm |
|
| 0 |
187 (100%) |
| htn |
|
| 0 |
72 (39%) |
| 1 |
115 (61%) |
| cad |
|
| 0 |
171 (91%) |
| 1 |
16 (8.6%) |
| cirrhosis |
|
| 0 |
186 (99%) |
| 1 |
1 (0.5%) |
| cancer_type |
|
| breast |
5 (2.7%) |
| cutaneous / melanoma |
130 (70%) |
| endocrine |
0 (0%) |
| gi |
3 (1.6%) |
| gu |
12 (6.4%) |
| gyn |
1 (0.5%) |
| head and neck |
1 (0.5%) |
| heme |
21 (11%) |
| neuro |
0 (0%) |
| sarcoma |
0 (0%) |
| thoracic |
14 (7.5%) |
| cancer_group |
|
| cutaneous / melanoma |
130 (70%) |
| gi |
3 (1.6%) |
| gu |
12 (6.4%) |
| gyn |
1 (0.5%) |
| other |
27 (14%) |
| thoracic |
14 (7.5%) |
| ace_arb |
|
| 0 |
112 (60%) |
| 1 |
75 (40%) |
| diu |
|
| 0 |
97 (52%) |
| 1 |
90 (48%) |
| ppi |
|
| 0 |
38 (20%) |
| 1 |
149 (80%) |
| steroids |
|
| 0 |
84 (45%) |
| 1 |
103 (55%) |
| smoking |
|
| 0 |
104 (56%) |
| 1 |
83 (44%) |
| statins |
|
| 0 |
89 (48%) |
| 1 |
98 (52%) |
| ICI_Class |
|
| PD1 |
86 (46%) |
| Combination |
36 (19%) |
| CTLA4 |
53 (28%) |
| PDL1 |
12 (6.4%) |
| nephrotoxic_chemo |
|
| 0 |
154 (82%) |
| 1 |
33 (18%) |
| pre_CRE_180days |
0.86 (0.75, 1.02) |
| pre_HGB_180days |
13.40 (12.00, 14.30) |
| pre_ALB_180days |
4.30 (4.10, 4.50) |
| eGFR_CRE_baseline |
91 (75, 102) |
10year
| Characteristic |
N = 67 |
| age_ici |
59 (49, 67) |
| male |
|
| 0 |
33 (49%) |
| 1 |
34 (51%) |
| Race |
|
| Asian |
0 (0%) |
| Black |
0 (0%) |
| Other/Unknown |
0 (0%) |
| White |
67 (100%) |
| Ethnic_Group |
|
| Hispanic |
0 (0%) |
| Non_hispanic |
63 (94%) |
| Other |
4 (6.0%) |
| ckd_incidence_10year |
|
| 0 |
58 (87%) |
| 1 |
9 (13%) |
| ckd_progression_10year |
|
| 0 |
66 (99%) |
| 1 |
1 (1.5%) |
| eskd_composite_10year |
|
| 0 |
67 (100%) |
| 1 |
0 (0%) |
| ckd_composite_10year |
10 (15%) |
| ckd_stage_1year |
|
| 1 |
32 (48%) |
| 2 |
27 (40%) |
| 3 |
8 (12%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_2year |
|
| 1 |
31 (46%) |
| 2 |
30 (45%) |
| 3 |
6 (9.0%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_3year |
|
| 1 |
30 (45%) |
| 2 |
30 (45%) |
| 3 |
7 (10%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_4year |
|
| 1 |
30 (45%) |
| 2 |
28 (42%) |
| 3 |
9 (13%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_5year |
|
| 1 |
30 (45%) |
| 2 |
29 (43%) |
| 3 |
8 (12%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_6year |
|
| 1 |
27 (40%) |
| 2 |
32 (48%) |
| 3 |
8 (12%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_7year |
|
| 1 |
28 (42%) |
| 2 |
31 (46%) |
| 3 |
8 (12%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_8year |
|
| 1 |
26 (39%) |
| 2 |
32 (48%) |
| 3 |
9 (13%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_9year |
|
| 1 |
29 (43%) |
| 2 |
30 (45%) |
| 3 |
8 (12%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_10year |
|
| 1 |
28 (42%) |
| 2 |
32 (48%) |
| 3 |
6 (9.0%) |
| 4 |
1 (1.5%) |
| 5 |
0 (0%) |
| ckd_stage_baseline |
|
| 1 |
38 (57%) |
| 2 |
22 (33%) |
| 3 |
7 (10%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
50 (75%) |
| 1 |
17 (25%) |
| dm |
|
| 0 |
67 (100%) |
| htn |
|
| 0 |
26 (39%) |
| 1 |
41 (61%) |
| cad |
|
| 0 |
62 (93%) |
| 1 |
5 (7.5%) |
| cirrhosis |
|
| 0 |
67 (100%) |
| 1 |
0 (0%) |
| cancer_type |
|
| breast |
2 (3.0%) |
| cutaneous / melanoma |
53 (79%) |
| endocrine |
0 (0%) |
| gi |
0 (0%) |
| gu |
3 (4.5%) |
| gyn |
0 (0%) |
| head and neck |
0 (0%) |
| heme |
5 (7.5%) |
| neuro |
0 (0%) |
| sarcoma |
0 (0%) |
| thoracic |
4 (6.0%) |
| cancer_group |
|
| cutaneous / melanoma |
53 (79%) |
| gi |
0 (0%) |
| gu |
3 (4.5%) |
| gyn |
0 (0%) |
| other |
7 (10%) |
| thoracic |
4 (6.0%) |
| ace_arb |
|
| 0 |
38 (57%) |
| 1 |
29 (43%) |
| diu |
|
| 0 |
34 (51%) |
| 1 |
33 (49%) |
| ppi |
|
| 0 |
15 (22%) |
| 1 |
52 (78%) |
| steroids |
|
| 0 |
39 (58%) |
| 1 |
28 (42%) |
| smoking |
|
| 0 |
33 (49%) |
| 1 |
34 (51%) |
| statins |
|
| 0 |
27 (40%) |
| 1 |
40 (60%) |
| ICI_Class |
|
| PD1 |
22 (33%) |
| Combination |
6 (9.0%) |
| CTLA4 |
37 (55%) |
| PDL1 |
2 (3.0%) |
| nephrotoxic_chemo |
|
| 0 |
59 (88%) |
| 1 |
8 (12%) |
| pre_CRE_180days |
0.86 (0.76, 1.02) |
| pre_HGB_180days |
13.70 (12.60, 14.50) |
| pre_ALB_180days |
4.40 (4.20, 4.70) |
| eGFR_CRE_baseline |
91 (76, 101) |
CIF survival all Event number : death + ckd composite
ckd_stage vs ckd_composite_1year
|
0
(N=7615) |
1
(N=312) |
Overall
(N=7927) |
| ckd_stage_baseline |
|
|
|
| 1 |
3729 (49.0%) |
68 (21.8%) |
3797 (47.9%) |
| 2 |
2992 (39.3%) |
210 (67.3%) |
3202 (40.4%) |
| 3 |
853 (11.2%) |
29 (9.3%) |
882 (11.1%) |
| 4 |
40 (0.5%) |
5 (1.6%) |
45 (0.6%) |
| 5 |
1 (0.0%) |
0 (0%) |
1 (0.0%) |
| factor(ckd_stage_1year) |
|
|
|
| 1 |
3345 (43.9%) |
1 (0.3%) |
3346 (42.2%) |
| 2 |
3271 (43.0%) |
58 (18.6%) |
3329 (42.0%) |
| 3 |
958 (12.6%) |
227 (72.8%) |
1185 (14.9%) |
| 4 |
38 (0.5%) |
23 (7.4%) |
61 (0.8%) |
| 5 |
3 (0.0%) |
3 (1.0%) |
6 (0.1%) |
ckd_stage vs ckd_composite_2year
|
0
(N=4699) |
1
(N=394) |
Overall
(N=5093) |
| ckd_stage_baseline |
|
|
|
| 1 |
2310 (49.2%) |
90 (22.8%) |
2400 (47.1%) |
| 2 |
1857 (39.5%) |
267 (67.8%) |
2124 (41.7%) |
| 3 |
510 (10.9%) |
34 (8.6%) |
544 (10.7%) |
| 4 |
21 (0.4%) |
3 (0.8%) |
24 (0.5%) |
| 5 |
1 (0.0%) |
0 (0%) |
1 (0.0%) |
| factor(ckd_stage_2year) |
|
|
|
| 1 |
1946 (41.4%) |
2 (0.5%) |
1948 (38.2%) |
| 2 |
2199 (46.8%) |
98 (24.9%) |
2297 (45.1%) |
| 3 |
533 (11.3%) |
277 (70.3%) |
810 (15.9%) |
| 4 |
21 (0.4%) |
15 (3.8%) |
36 (0.7%) |
| 5 |
0 (0%) |
2 (0.5%) |
2 (0.0%) |
ckd_stage vs ckd_composite_3year
|
0
(N=2875) |
1
(N=334) |
Overall
(N=3209) |
| ckd_stage_baseline |
|
|
|
| 1 |
1434 (49.9%) |
79 (23.7%) |
1513 (47.1%) |
| 2 |
1132 (39.4%) |
217 (65.0%) |
1349 (42.0%) |
| 3 |
302 (10.5%) |
34 (10.2%) |
336 (10.5%) |
| 4 |
6 (0.2%) |
4 (1.2%) |
10 (0.3%) |
| 5 |
1 (0.0%) |
0 (0%) |
1 (0.0%) |
| factor(ckd_stage_3year) |
|
|
|
| 1 |
1155 (40.2%) |
8 (2.4%) |
1163 (36.2%) |
| 2 |
1416 (49.3%) |
113 (33.8%) |
1529 (47.6%) |
| 3 |
290 (10.1%) |
192 (57.5%) |
482 (15.0%) |
| 4 |
14 (0.5%) |
16 (4.8%) |
30 (0.9%) |
| 5 |
0 (0%) |
5 (1.5%) |
5 (0.2%) |
ckd_stage vs ckd_composite_4year
|
0
(N=1894) |
1
(N=261) |
Overall
(N=2155) |
| ckd_stage_baseline |
|
|
|
| 1 |
985 (52.0%) |
63 (24.1%) |
1048 (48.6%) |
| 2 |
716 (37.8%) |
173 (66.3%) |
889 (41.3%) |
| 3 |
189 (10.0%) |
24 (9.2%) |
213 (9.9%) |
| 4 |
3 (0.2%) |
1 (0.4%) |
4 (0.2%) |
| 5 |
1 (0.1%) |
0 (0%) |
1 (0.0%) |
| factor(ckd_stage_4year) |
|
|
|
| 1 |
788 (41.6%) |
12 (4.6%) |
800 (37.1%) |
| 2 |
919 (48.5%) |
78 (29.9%) |
997 (46.3%) |
| 3 |
180 (9.5%) |
158 (60.5%) |
338 (15.7%) |
| 4 |
7 (0.4%) |
12 (4.6%) |
19 (0.9%) |
| 5 |
0 (0%) |
1 (0.4%) |
1 (0.0%) |
ckd_stage vs ckd_composite_5year
|
0
(N=1276) |
1
(N=208) |
Overall
(N=1484) |
| ckd_stage_baseline |
|
|
|
| 1 |
685 (53.7%) |
56 (26.9%) |
741 (49.9%) |
| 2 |
475 (37.2%) |
129 (62.0%) |
604 (40.7%) |
| 3 |
114 (8.9%) |
22 (10.6%) |
136 (9.2%) |
| 4 |
2 (0.2%) |
1 (0.5%) |
3 (0.2%) |
| 5 |
0 (0%) |
0 (0%) |
0 (0%) |
| factor(ckd_stage_5year) |
|
|
|
| 1 |
559 (43.8%) |
8 (3.8%) |
567 (38.2%) |
| 2 |
595 (46.6%) |
85 (40.9%) |
680 (45.8%) |
| 3 |
120 (9.4%) |
103 (49.5%) |
223 (15.0%) |
| 4 |
2 (0.2%) |
10 (4.8%) |
12 (0.8%) |
| 5 |
0 (0%) |
2 (1.0%) |
2 (0.1%) |
Table 5 year aki
|
Overall
(N=208) |
| aki |
|
| 0 |
95 (45.7%) |
| 1 |
113 (54.3%) |
| as.factor(aki_before_ckd) |
|
| 0 |
38 (18.3%) |
| 1 |
75 (36.1%) |
| Missing |
95 (45.7%) |
|
Overall
(N=15065) |
| aki |
|
| 0 |
10967 (72.8%) |
| 1 |
4098 (27.2%) |
| as.factor(aki_before_ckd) |
|
| 0 |
164 (1.1%) |
| 1 |
346 (2.3%) |
| Missing |
14555 (96.6%) |
| ckd_composite |
|
| 0 |
14188 (94.2%) |
| 1 |
877 (5.8%) |
Table ckd_composite==1 columns:aki_before_ckd
| Characteristic |
N = 825 |
| age_ici |
70 (63, 76) |
| male |
|
| 0 |
423 (51%) |
| 1 |
402 (49%) |
| Race |
|
| Asian |
19 (2.3%) |
| Black |
15 (1.8%) |
| Other/Unknown |
24 (2.9%) |
| White |
767 (93%) |
| Ethnic_Group |
|
| Hispanic |
12 (1.5%) |
| Non_hispanic |
766 (93%) |
| Other |
47 (5.7%) |
| ckd_incidence_1year |
|
| 0 |
556 (67%) |
| 1 |
269 (33%) |
| ckd_progression_1year |
|
| 0 |
798 (97%) |
| 1 |
27 (3.3%) |
| eskd_composite_1year |
|
| 0 |
806 (98%) |
| 1 |
19 (2.3%) |
| ckd_composite_1year |
|
| 0 |
513 (62%) |
| 1 |
312 (38%) |
| ckd_stage_1year |
|
| 1 |
62 (7.5%) |
| 2 |
368 (45%) |
| 3 |
364 (44%) |
| 4 |
28 (3.4%) |
| 5 |
3 (0.4%) |
| ckd_stage_baseline |
|
| 1 |
195 (24%) |
| 2 |
524 (64%) |
| 3 |
100 (12%) |
| 4 |
6 (0.7%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
357 (43%) |
| 1 |
468 (57%) |
| dm |
|
| 0 |
825 (100%) |
| htn |
|
| 0 |
296 (36%) |
| 1 |
529 (64%) |
| cad |
|
| 0 |
659 (80%) |
| 1 |
166 (20%) |
| cirrhosis |
|
| 0 |
815 (99%) |
| 1 |
10 (1.2%) |
| cancer_type |
|
| breast |
31 (3.8%) |
| cutaneous / melanoma |
153 (19%) |
| endocrine |
1 (0.1%) |
| gi |
88 (11%) |
| gu |
147 (18%) |
| gyn |
37 (4.5%) |
| head and neck |
39 (4.7%) |
| heme |
31 (3.8%) |
| neuro |
11 (1.3%) |
| sarcoma |
7 (0.8%) |
| thoracic |
280 (34%) |
| cancer_group |
|
| cutaneous / melanoma |
153 (19%) |
| gi |
88 (11%) |
| gu |
147 (18%) |
| gyn |
37 (4.5%) |
| other |
120 (15%) |
| thoracic |
280 (34%) |
| ace_arb |
|
| 0 |
364 (44%) |
| 1 |
461 (56%) |
| diu |
|
| 0 |
286 (35%) |
| 1 |
539 (65%) |
| ppi |
|
| 0 |
185 (22%) |
| 1 |
640 (78%) |
| steroids |
|
| 0 |
252 (31%) |
| 1 |
573 (69%) |
| smoking |
|
| 0 |
345 (42%) |
| 1 |
480 (58%) |
| statins |
|
| 0 |
354 (43%) |
| 1 |
471 (57%) |
| ICI_Class |
|
| PD1 |
560 (68%) |
| Combination |
94 (11%) |
| CTLA4 |
49 (5.9%) |
| PDL1 |
122 (15%) |
| nephrotoxic_chemo |
|
| 0 |
434 (53%) |
| 1 |
391 (47%) |
| pre_CRE_180days |
0.91 (0.78, 1.08) |
| pre_HGB_180days |
12.50 (11.20, 13.60) |
| pre_ALB_180days |
4.00 (3.80, 4.30) |
| eGFR_CRE_baseline |
79 (68, 89) |
| Characteristic |
0
N = 531 |
1
N = 346 |
| age_ici |
70 (63, 76) |
69 (62, 75) |
| male |
|
|
| 0 |
270 (51%) |
176 (51%) |
| 1 |
261 (49%) |
170 (49%) |
| Race |
|
|
| Asian |
16 (3.0%) |
7 (2.0%) |
| Black |
11 (2.1%) |
6 (1.7%) |
| Other/Unknown |
20 (3.8%) |
8 (2.3%) |
| White |
484 (91%) |
325 (94%) |
| Ethnic_Group |
|
|
| Hispanic |
6 (1.1%) |
6 (1.7%) |
| Non_hispanic |
492 (93%) |
323 (93%) |
| Other |
33 (6.2%) |
17 (4.9%) |
| ckd_composite |
|
|
| 0 |
0 (0%) |
0 (0%) |
| 1 |
531 (100%) |
346 (100%) |
| ckd_incidence |
|
|
| 0 |
77 (15%) |
72 (21%) |
| 1 |
454 (85%) |
274 (79%) |
| ckd_progression |
|
|
| 0 |
469 (88%) |
304 (88%) |
| 1 |
62 (12%) |
42 (12%) |
| ckd_stage_baseline |
|
|
| 1 |
111 (21%) |
94 (27%) |
| 2 |
353 (66%) |
200 (58%) |
| 3 |
63 (12%) |
46 (13%) |
| 4 |
4 (0.8%) |
6 (1.7%) |
| 5 |
0 (0%) |
0 (0%) |
| aki |
|
|
| 0 |
367 (69%) |
0 (0%) |
| 1 |
164 (31%) |
346 (100%) |
| dm |
|
|
| 0 |
531 (100%) |
346 (100%) |
| htn |
|
|
| 0 |
181 (34%) |
131 (38%) |
| 1 |
350 (66%) |
215 (62%) |
| cad |
|
|
| 0 |
417 (79%) |
279 (81%) |
| 1 |
114 (21%) |
67 (19%) |
| cirrhosis |
|
|
| 0 |
526 (99%) |
338 (98%) |
| 1 |
5 (0.9%) |
8 (2.3%) |
| ace_arb |
|
|
| 0 |
256 (48%) |
134 (39%) |
| 1 |
275 (52%) |
212 (61%) |
| diu |
|
|
| 0 |
204 (38%) |
96 (28%) |
| 1 |
327 (62%) |
250 (72%) |
| ppi |
|
|
| 0 |
147 (28%) |
53 (15%) |
| 1 |
384 (72%) |
293 (85%) |
| steroids |
|
|
| 0 |
158 (30%) |
110 (32%) |
| 1 |
373 (70%) |
236 (68%) |
| smoking |
|
|
| 0 |
229 (43%) |
139 (40%) |
| 1 |
302 (57%) |
207 (60%) |
| statins |
|
|
| 0 |
244 (46%) |
138 (40%) |
| 1 |
287 (54%) |
208 (60%) |
| ICI_Class |
|
|
| PD1 |
357 (67%) |
233 (67%) |
| Combination |
56 (11%) |
44 (13%) |
| CTLA4 |
29 (5.5%) |
24 (6.9%) |
| PDL1 |
89 (17%) |
45 (13%) |
| nephrotoxic_chemo |
|
|
| 0 |
276 (52%) |
184 (53%) |
| 1 |
255 (48%) |
162 (47%) |
| pre_CRE_180days |
0.93 (0.80, 1.10) |
0.89 (0.77, 1.09) |
| pre_HGB_180days |
12.40 (11.20, 13.50) |
12.50 (11.10, 13.70) |
| pre_ALB_180days |
4.10 (3.80, 4.30) |
4.00 (3.70, 4.30) |
| eGFR_CRE_baseline |
78 (67, 88) |
79 (68, 91) |
logistic regression outcome: ckd_composite_5year
| Characteristic |
N |
OR |
95% CI |
p-value |
| year_10 |
1,484 |
1.70 |
1.49, 1.95 |
<0.001 |
| male |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.79 |
0.59, 1.05 |
0.109 |
| Race |
1,484 |
|
|
|
| Asian |
|
— |
— |
|
| Black |
|
0.89 |
0.12, 4.77 |
0.899 |
| Other/Unknown |
|
0.41 |
0.08, 1.82 |
0.252 |
| White |
|
0.96 |
0.40, 2.86 |
0.939 |
| htn |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.74 |
1.28, 2.39 |
<0.001 |
| cad |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.21 |
0.82, 1.76 |
0.330 |
| cirrhosis |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.61 |
0.03, 3.22 |
0.640 |
| ace_arb |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
2.20 |
1.64, 2.98 |
<0.001 |
| diu |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
2.21 |
1.63, 3.02 |
<0.001 |
| ppi |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.74 |
1.20, 2.59 |
0.005 |
| steroids |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.86 |
0.63, 1.18 |
0.335 |
| smoking |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.85 |
1.37, 2.51 |
<0.001 |
| statins |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.60 |
1.19, 2.16 |
0.002 |
| nephrotoxic_chemo |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.40 |
1.03, 1.89 |
0.029 |
| Bevacizumab |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.51 |
0.78, 2.73 |
0.197 |
| Cisplatin |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.34 |
0.85, 2.04 |
0.193 |
| Carboplatin |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.52 |
1.08, 2.13 |
0.016 |
| Pemetrexed |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.65 |
1.06, 2.51 |
0.022 |
| Gemcitabine |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.26 |
0.74, 2.05 |
0.362 |
| Cetuximab |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.00 |
|
0.969 |
| Trastuzumab |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.87 |
0.26, 2.26 |
0.803 |
| eGFR_CRE_baseline_decrease_10 |
1,484 |
1.28 |
1.18, 1.37 |
<0.001 |
| ICI_Class |
1,484 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
0.81 |
0.49, 1.28 |
0.378 |
| CTLA4 |
|
1.13 |
0.64, 1.91 |
0.657 |
| PDL1 |
|
1.22 |
0.78, 1.87 |
0.368 |
| cancer_group |
1,484 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
2.58 |
1.33, 4.78 |
0.003 |
| gu |
|
2.16 |
1.36, 3.40 |
<0.001 |
| gyn |
|
2.03 |
0.93, 4.11 |
0.060 |
| other |
|
0.97 |
0.60, 1.54 |
0.905 |
| thoracic |
|
2.19 |
1.48, 3.24 |
<0.001 |
Multivariate logistic regression outcome: ckd_composite_5year
| Characteristic |
N |
OR |
95% CI |
p-value |
| year_10 |
1,484 |
1.62 |
1.37, 1.92 |
<0.001 |
| male |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.74 |
0.53, 1.02 |
0.067 |
| htn |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.07 |
0.76, 1.52 |
0.697 |
| cad |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.82 |
0.53, 1.23 |
0.346 |
| ppi |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.54 |
1.03, 2.34 |
0.039 |
| smoking |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.36 |
0.97, 1.90 |
0.073 |
| eGFR_CRE_baseline_decrease_10 |
1,484 |
1.10 |
1.00, 1.21 |
0.055 |
| nephrotoxic_chemo |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.07 |
0.73, 1.55 |
0.730 |
| ICI_Class |
1,484 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.23 |
0.72, 2.03 |
0.442 |
| CTLA4 |
|
2.00 |
1.07, 3.62 |
0.025 |
| PDL1 |
|
0.94 |
0.58, 1.50 |
0.813 |
| cancer_group |
1,484 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
2.81 |
1.39, 5.46 |
0.003 |
| gu |
|
2.08 |
1.20, 3.58 |
0.008 |
| gyn |
|
1.91 |
0.79, 4.34 |
0.132 |
| other |
|
1.31 |
0.77, 2.18 |
0.312 |
| thoracic |
|
1.92 |
1.16, 3.17 |
0.011 |
Multivariate logistic regression outcome: ckd_composite_5year
| Characteristic |
N |
OR |
95% CI |
p-value |
| year_10 |
1,484 |
1.64 |
1.39, 1.95 |
<0.001 |
| male |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.76 |
0.55, 1.05 |
0.100 |
| htn |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.05 |
0.74, 1.50 |
0.780 |
| cad |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.84 |
0.54, 1.26 |
0.400 |
| ppi |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.52 |
1.02, 2.32 |
0.046 |
| smoking |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.36 |
0.97, 1.90 |
0.077 |
| eGFR_CRE_baseline_decrease_10 |
1,484 |
1.10 |
1.00, 1.21 |
0.054 |
| Bevacizumab |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.33 |
0.64, 2.64 |
0.424 |
| Cisplatin |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.27 |
0.75, 2.12 |
0.367 |
| Carboplatin |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.30 |
0.81, 2.06 |
0.269 |
| Pemetrexed |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.93 |
0.50, 1.71 |
0.813 |
| Gemcitabine |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.73 |
0.39, 1.33 |
0.318 |
| Cetuximab |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.00 |
|
0.979 |
| Trastuzumab |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.32 |
0.36, 3.90 |
0.639 |
| ICI_Class |
1,484 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.22 |
0.71, 2.03 |
0.449 |
| CTLA4 |
|
2.02 |
1.07, 3.66 |
0.024 |
| PDL1 |
|
0.89 |
0.54, 1.43 |
0.641 |
| cancer_group |
1,484 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
2.80 |
1.38, 5.47 |
0.003 |
| gu |
|
2.15 |
1.23, 3.74 |
0.007 |
| gyn |
|
1.59 |
0.62, 3.82 |
0.315 |
| other |
|
1.33 |
0.78, 2.22 |
0.286 |
| thoracic |
|
1.79 |
1.04, 3.06 |
0.034 |
Multivariate logistic regression outcome: ckd_composite_5year
| Characteristic |
N |
OR |
95% CI |
p-value |
| year_10 |
1,484 |
1.62 |
1.37, 1.93 |
<0.001 |
| male |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.74 |
0.53, 1.02 |
0.070 |
| htn |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.07 |
0.76, 1.53 |
0.692 |
| cad |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.82 |
0.53, 1.23 |
0.351 |
| ppi |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.54 |
1.03, 2.35 |
0.039 |
| smoking |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.36 |
0.97, 1.90 |
0.073 |
| eGFR_CRE_baseline_decrease_10 |
1,484 |
1.10 |
1.00, 1.21 |
0.055 |
| nephrotoxic_chemo |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.07 |
0.73, 1.55 |
0.731 |
| statins |
1,484 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.99 |
0.70, 1.39 |
0.941 |
| ICI_Class |
1,484 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.23 |
0.72, 2.03 |
0.441 |
| CTLA4 |
|
2.01 |
1.07, 3.63 |
0.025 |
| PDL1 |
|
0.94 |
0.58, 1.50 |
0.814 |
| cancer_group |
1,484 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
2.80 |
1.39, 5.46 |
0.003 |
| gu |
|
2.08 |
1.20, 3.58 |
0.008 |
| gyn |
|
1.91 |
0.79, 4.34 |
0.132 |
| other |
|
1.31 |
0.77, 2.18 |
0.311 |
| thoracic |
|
1.92 |
1.16, 3.18 |
0.011 |
Fine & Grey model for all
| Characteristic |
N |
HR |
95% CI |
p-value |
| year_10 |
15,065 |
1.39 |
1.33, 1.46 |
<0.001 |
| male |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.89 |
0.78, 1.02 |
0.085 |
| Race |
15,065 |
|
|
|
| Asian |
|
— |
— |
|
| Black |
|
0.95 |
0.51, 1.77 |
0.860 |
| Other/Unknown |
|
0.98 |
0.56, 1.70 |
0.940 |
| White |
|
1.21 |
0.80, 1.83 |
0.360 |
| htn |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.39 |
1.21, 1.60 |
<0.001 |
| cad |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.04 |
0.88, 1.22 |
0.670 |
| cirrhosis |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.79 |
0.46, 1.36 |
0.390 |
| ace_arb |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
2.08 |
1.82, 2.38 |
<0.001 |
| diu |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.83 |
1.59, 2.11 |
<0.001 |
| ppi |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.33 |
1.14, 1.56 |
<0.001 |
| steroids |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.82 |
0.71, 0.95 |
0.006 |
| smoking |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.43 |
1.25, 1.64 |
<0.001 |
| statins |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.81 |
1.59, 2.07 |
<0.001 |
| nephrotoxic_chemo |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.97 |
0.85, 1.11 |
0.670 |
| Bevacizumab |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.69 |
0.51, 0.92 |
0.013 |
| Cisplatin |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.12 |
0.92, 1.35 |
0.250 |
| Carboplatin |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.04 |
0.90, 1.20 |
0.600 |
| Pemetrexed |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.72 |
1.46, 2.02 |
<0.001 |
| Gemcitabine |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.16 |
0.95, 1.41 |
0.140 |
| Cetuximab |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.45 |
0.24, 0.84 |
0.012 |
| Trastuzumab |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.78 |
0.49, 1.22 |
0.280 |
| eGFR_CRE_baseline_decrease_10 |
15,065 |
1.20 |
1.18, 1.23 |
<0.001 |
| ICI_Class |
15,065 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.02 |
0.83, 1.26 |
0.850 |
| CTLA4 |
|
1.37 |
1.04, 1.81 |
0.026 |
| PDL1 |
|
1.12 |
0.93, 1.35 |
0.230 |
| cancer_group |
15,065 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
0.79 |
0.61, 1.01 |
0.064 |
| gu |
|
1.54 |
1.24, 1.91 |
<0.001 |
| gyn |
|
0.80 |
0.57, 1.14 |
0.210 |
| other |
|
0.56 |
0.45, 0.71 |
<0.001 |
| thoracic |
|
1.17 |
0.97, 1.42 |
0.100 |
Fine & Grey model for all multivaiate model
| Characteristic |
N |
HR |
95% CI |
p-value |
| year_10 |
15,065 |
1.27 |
1.19, 1.36 |
<0.001 |
| male |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.81 |
0.71, 0.93 |
0.004 |
| htn |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.04 |
0.90, 1.21 |
0.6 |
| cad |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.78 |
0.66, 0.92 |
0.004 |
| ppi |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.33 |
1.12, 1.57 |
<0.001 |
| smoking |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.24 |
1.07, 1.43 |
0.004 |
| eGFR_CRE_baseline_decrease_10 |
15,065 |
1.10 |
1.07, 1.14 |
<0.001 |
| Bevacizumab |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.90 |
0.67, 1.22 |
0.5 |
| Cisplatin |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.02 |
0.83, 1.27 |
0.8 |
| Carboplatin |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.87 |
0.73, 1.04 |
0.12 |
| Pemetrexed |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.77 |
1.42, 2.21 |
<0.001 |
| Gemcitabine |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.05 |
0.84, 1.31 |
0.6 |
| Cetuximab |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.73 |
0.39, 1.39 |
0.3 |
| Trastuzumab |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.09 |
0.68, 1.74 |
0.7 |
| ICI_Class |
15,065 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.07 |
0.86, 1.34 |
0.5 |
| CTLA4 |
|
1.48 |
1.10, 1.98 |
0.009 |
| PDL1 |
|
1.06 |
0.87, 1.28 |
0.6 |
| cancer_group |
15,065 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
0.88 |
0.67, 1.15 |
0.3 |
| gu |
|
1.32 |
1.02, 1.69 |
0.031 |
| gyn |
|
0.82 |
0.56, 1.19 |
0.3 |
| other |
|
0.72 |
0.56, 0.92 |
0.009 |
| thoracic |
|
0.88 |
0.69, 1.12 |
0.3 |
Fine & Grey model for all multivaiate model
| Characteristic |
N |
HR |
95% CI |
p-value |
| year_10 |
15,065 |
1.26 |
1.18, 1.35 |
<0.001 |
| male |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.80 |
0.70, 0.92 |
0.002 |
| htn |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.05 |
0.90, 1.22 |
0.5 |
| cad |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.77 |
0.65, 0.92 |
0.004 |
| ppi |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.35 |
1.14, 1.60 |
<0.001 |
| smoking |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.25 |
1.09, 1.45 |
0.002 |
| eGFR_CRE_baseline_decrease_10 |
15,065 |
1.11 |
1.07, 1.14 |
<0.001 |
| nephrotoxic_chemo |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.01 |
0.86, 1.17 |
>0.9 |
| ICI_Class |
15,065 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.04 |
0.84, 1.30 |
0.7 |
| CTLA4 |
|
1.46 |
1.09, 1.96 |
0.011 |
| PDL1 |
|
1.00 |
0.83, 1.22 |
>0.9 |
| cancer_group |
15,065 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
0.89 |
0.68, 1.16 |
0.4 |
| gu |
|
1.33 |
1.04, 1.70 |
0.021 |
| gyn |
|
0.77 |
0.53, 1.12 |
0.2 |
| other |
|
0.68 |
0.53, 0.88 |
0.003 |
| thoracic |
|
1.08 |
0.86, 1.35 |
0.5 |
Fine & Grey model for all multivaiate model
| Characteristic |
N |
HR |
95% CI |
p-value |
| year_10 |
15,065 |
1.23 |
1.15, 1.31 |
<0.001 |
| male |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.79 |
0.68, 0.90 |
<0.001 |
| htn |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.00 |
0.85, 1.16 |
>0.9 |
| cad |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.73 |
0.62, 0.87 |
<0.001 |
| ppi |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.31 |
1.11, 1.55 |
0.002 |
| smoking |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.23 |
1.06, 1.42 |
0.005 |
| eGFR_CRE_baseline_decrease_10 |
15,065 |
1.10 |
1.06, 1.14 |
<0.001 |
| nephrotoxic_chemo |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.00 |
0.86, 1.16 |
>0.9 |
| statins |
15,065 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.37 |
1.18, 1.59 |
<0.001 |
| ICI_Class |
15,065 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.04 |
0.84, 1.30 |
0.7 |
| CTLA4 |
|
1.46 |
1.09, 1.96 |
0.011 |
| PDL1 |
|
1.00 |
0.82, 1.21 |
>0.9 |
| cancer_group |
15,065 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
0.92 |
0.70, 1.20 |
0.5 |
| gu |
|
1.36 |
1.06, 1.73 |
0.014 |
| gyn |
|
0.80 |
0.55, 1.16 |
0.2 |
| other |
|
0.70 |
0.54, 0.90 |
0.005 |
| thoracic |
|
1.08 |
0.87, 1.35 |
0.5 |